The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear winner: while both drugs work well to prevent recurrent blood clots, apixaban is safer than rivaroxaban, with fewer bleeding complications. Venous thrombosis occurs when a blood clot lodges in the veins of the legs or lungs. … Read more
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have found that depleting a clotting protein made by the liver could slow down pancreatic cancer. The research, recently published in Gastroenterology and led by Melissa L. Fishel, PhD, shows that reducing fibrinogen in mouse models shrinks primary pancreatic ductal adenocarcinoma (PDAC) tumors and reduces their ability to … Read more
Venous thromboembolism (VTE) is a life-threatening complication in children with serious underlying conditions such as heart defects or cancer. Treatment or prevention of thrombosis poses an additional challenge in everyday clinical practice. A therapy using the active ingredient rivaroxaban specifically tailored to children was successfully tested for the first time in 2020. Now, long-term data … Read more
Acute coronary syndrome (ACS) in patients with SARS-CoV-2 infection represents a critical intersection of viral-induced inflammation and cardiovascular pathology. This review explores the dual mechanisms driving SARS-CoV-2-associated ACS and evaluates emerging therapeutic strategies, including phytomedicine and nanotechnology, to address both viral and cardiovascular complications. SARS-CoV-2 and ACS pathogenesis SARS-CoV-2 infection exacerbates ACS through systemic inflammation, … Read more
TOPLINE: Anti–transcription factor A, mitochondrial (anti-TFAM) antibodies in patients with systemic lupus erythematosus (SLE) were associated with a threefold increased risk for thrombotic events. METHODOLOGY: Researchers discovered the autoantibody in an exploratory sample of 22 patients with SLE and nine healthy controls. The findings were validated using a sample of 158 patients with SLE and … Read more
A new study – just published in Nursing Research – has uncovered concerning disparities in patient outcomes, specifically related to nursing care, within hospitals that predominantly serve Black communities. The research, which analyzed data from over 3,000 hospitals across the United States, reveals that these Black-serving hospitals (BSHs) exhibit significantly higher rates of specific adverse … Read more
Results of a nationwide Swedish population-based study indicate that patients with myelofibrosis (MF) have increased rates of thromboembolic events and major bleeding compared with presentations in other myeloproliferative neoplasms (MPN), with thromboembolic complications and major bleeding events diverging based on varying treatment groups. These results, published by study authors in Blood Advances, can help health … Read more
TOPLINE: Patients with cerebral venous thrombosis (CVT) had a threefold higher risk for cancer than individuals in the general population, according to a new study. Men older than 50 years had the highest absolute risk, whereas younger patients had the highest relative risk. METHODOLOGY: A population-based cohort study analysed data from the Dutch Hospital Discharge … Read more
Summary: Exposure to long-wavelength red light significantly reduced blood clot formation in both mice and human studies. Red light was associated with lower inflammation, reduced immune system activation, and fewer clot-promoting mechanisms, such as neutrophil extracellular traps (NETs) and platelet activation. Unlike blue or white light, red light influenced clotting through optic pathways, suggesting its … Read more
Title: Unveiling the Power of Red Light: A Revolutionary Approach to Blood Clot Prevention Introduction In a groundbreaking study, researchers have discovered that exposure to long-wavelength red light… The post Red Light Reduces Blood Clot Formation appeared first on NewsyList. Source link